NOiAmSpartacus
$AUPH With the new CAGR projection in LN growth and getting patent to 2042…let’s do math!
BO case: $400M sales growing 8% CAGR, plus 5% annual market share gains from Big Pharma scale (way conservative) = ~13.4% annual growth. That implies roughly $11B cumulative 12-year sales and ~$9.9B cumulative profit at a 90% margin. Add $380M cash and the potential tax value of the $500M write-off. A strategic buyer could justify roughly $5–6B, subject to patent strength, execution, and verification of margins.
AUR200 value with best in class results in 4 indications? 🤯 Oh and Kezar asset cleared 💵
$45 Minimum 🎯…Just Saying!’
2
31
